- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 4, 2024Trust & Estate Litigation in Minnesota
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Consumer Alert: Latest News on VIOXX Recall
April 27, 2005
We are continuing to review claims related to the pain reliever VIOXX, which was withdrawn from the market on September 30, 2004 by Merck & Co., Inc. after a long-term clinical trial demonstrated an increased risk of heart attacks and strokes.
Launched by Merck in 1999, VIOXX is a non-steroidal anti-inflammatory drug (“NSAID”) known as a COX-2 inhibitor. Due to Merck's aggressive promotion, VIOXX quickly became a hugely popular prescription pain reliever for the treatment of osteoarthritis, acute pain, menstrual pain and rheumatoid arthritis. Worldwide sales of VIOXX in 2003 were $2.5 billion.
The clinical trial leading to the withdrawal of VIOXX was not the first to raise suspicion about the safety of VIOXX. By early 2000, results from the VIGOR (VIOXX Gastrointestinal Outcomes Research) study also indicated an increased risk of cardiovascular events compared to another painkiller. The FDA sent a warning letter to Merck in 2001 calling Merck's promotional campaign for VIOXX “false and misleading” because it minimized the potentially serious findings in the VIGOR trial. Merck never put the cardiovascular risks associated with taking VIOXX in the Warning sections of the labeling for its multi-billion-dollar-a-year drug.
On September 30, 2004, FDA issued a Public Advisory to inform patients of Merck's actions and to advise them to see their doctors for alternative medications.
Robins, Kaplan, Miller & Ciresi L.L.P. is actively involved in VIOXX litigation. In fact, our attorney Roberta B. Walburn (who was a leader in the State of Minnesota's successful lawsuit against Big Tobacco) was recently appointed a Vice-Chair of the Plaintiffs' Science Committee in the consolidated federal VIOXX proceedings in United States District Court in Louisiana. Ms. Walburn will also chair the Medical Communications/Learned Intermediary sub-committee. The firm further represents dozens of clients from across Minnesota and the country who suffered life-altering injuries as a result of taking VIOXX.
If you or your loved one has taken VIOXX and suffered a heart attack or stroke, you may want more information. Please feel free to contact Tara Sutton or send an e-mail by clicking here: contact us.
Related Articles: Vioxx Pulled Off the Market Because of Increased Risk of Heart Attack and Stroke
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.